Yellow fever immunizations: Indications and risks

Wilson, Mary; Chen, Lin H.; Barnett, Elizabeth D.

doi:10.1007/s11908-004-0022-5

Cited by 22 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this still means that 2% of people will become sick. [21][22][23][24] The current study examines the gender distribution of Covid-19 cases, demonstrating a significant male preponderance over girls, a tendency supported by earlier research. It consistently shows that males have a higher incidence of Covid-19 than females.…”

Section: Resultssupporting

confidence: 59%

The Vax effect: Role of global vaccination initiatives in pandemic control and impact in Dehradun during COVID-19

Singh,

Gurada,

Mahendru

et al. 2024

IJCBR

View full text Add to dashboard Cite

COVID-19 was one of the most contagious diseases spread throughout the world and caused by the Corona virus. Its cellular and molecular profiling was performed on individuals suffering from Covid-19-like sickness in Dehradun. During this investigation, 100 random samples were taken from patients. Real Time PCR amplification of suspected cases of Covid-19 was done where 68% of the cases were positive. The proportions and patterns of positive cases and hospital admissions for covid-19 in the third wave in Dehradun were significantly different when compared to the first and second waves. This disparity was caused by a number of factors, including changes in lifestyle, natural immunological ability to cope with recent waves of natural infections, and the most important factor, which was that more than 83% of people over the age of 18 years had received the first or both doses of the vaccine. The Covid-19 vaccines were so effective due to which there was a very low rate of serious infection, hospitalization, and mortality.

show abstract

Section: Resultssupporting

confidence: 59%

The Vax effect: Role of global vaccination initiatives in pandemic control and impact in Dehradun during COVID-19

Singh,

Gurada,

Mahendru

et al. 2024

IJCBR

View full text Add to dashboard Cite

show abstract

“…The YF 17D-204 vaccine has a very good safety record, with only rare cases of serious adverse effects following immunization of healthy individuals (allergic reactions, 1 in 131 000 persons; vaccine-related neurological disease, 1 in 250 000 persons; and vaccine-related viscerotropic disease, 1 in 300 000 persons). 13,14 In nonepidemic areas of Africa, the risk of contracting YF in unvaccinated subjects has been estimated to be 1 in 2000; of these, 1 in 7 individuals develops clinical illness and 1 in 10 000 dies from the disease. Rates are 10 times lower for South America.…”

Section: Commentmentioning

confidence: 99%

Yellow Fever Vaccination and Increased Relapse Rate in Travelers With Multiple Sclerosis

Farez

Correale²

2011

Arch Neurol

View full text Add to dashboard Cite

To investigate the effect of yellow fever (YF) immunization on the subsequent multiple sclerosis (MS) relapse risk. Design: Self-controlled case series study. Setting: An MS outpatient clinic. Patients: Seven patients with clinical relapsingremitting MS traveling to endemic YF areas who received the YF 17D-204 vaccine were studied. Intervention: The YF 17D-204 vaccine. Main Outcome Measure: Number of relapses. Secondary outcomes included the number of new lesions on magnetic resonance imaging and peripheral mononuclear cell cytokine and chemokine production. Results: The annual exacerbation rate during risk periods following immunization was 8.57, while the relapse rate outside the risk period was only 0.67 (rate ra-tio=12.778; PϽ.001). Three months after immunization, patients showed a significant increase in new or enlarging T2-weighted lesions and gadolinium-enhancing lesions compared with 12 months prior to vaccination and 9 months after immunization (both P Ͻ .001). Moreover, blood myelin basic protein and myelin oligodendrocyte glycoprotein responses showed significant increases in interferon ␥-induced protein 10 kDa-, interferon ␥-, interleukin 1␣-, interleukin 1␤-, and tumor necrosis factor-secreting cell numbers as well as complement component C1qB production after YF vaccination in patients with MS compared with unvaccinated patients with MS, patients with MS vaccinated against influenza, and healthy control subjects (P=.01 and P Ͻ.001, respectively). Conclusion: For patients with MS traveling to endemic YF areas, vaccination should be recommended on the basis of carefully weighing the risk of exacerbation against the likelihood of exposure to the YF virus.

show abstract

“…[1][2][3] Because there is no effective treatment for YF, prevention through immunization is critical to lower morbidity and mortality.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Gotuzzo¹,

Yactayo²,

Córdova³

2013

The American Society of Tropical Medicine and Hygiene

207

179

View full text Add to dashboard Cite

Abstract. Current regulations stipulate a yellow fever (YF) booster every 10 years. We conducted a systematic review of the protective efficacy and duration of immunity of YF vaccine in residents of disease-endemic areas and in travelers to assess the need for a booster in these two settings and in selected populations (human immunodeficiency virus-infected persons, infants, children, pregnant women, and severely malnourished persons). Thirty-six studies and 22 reports were included. We identified 12 studies of immunogenicity, 8 of duration of immunity, 8 of vaccine response in infants and children, 7 of human-immunodeficiency virus-infected persons, 2 of pregnant women, and 1 of severely malnourished children. Based on currently available data, a single dose of YF vaccine is highly immunogenic and confers sustained life-long protective immunity against YF. Therefore, a booster dose of YF vaccine is not needed. Special considerations for selected populations are detailed.

show abstract

Yellow fever immunizations: Indications and risks

Cited by 22 publications

References 33 publications

The Vax effect: Role of global vaccination initiatives in pandemic control and impact in Dehradun during COVID-19

The Vax effect: Role of global vaccination initiatives in pandemic control and impact in Dehradun during COVID-19

Yellow Fever Vaccination and Increased Relapse Rate in Travelers With Multiple Sclerosis

Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years

Contact Info

Product

Resources

About